Plasmid DNA vaccine for brain cancer enters Phase I trial
Immunomic Therapeutics has commenced its Phase I clinical trial evaluating ITI-1001, a plasmid DNA (pDNA) vaccine, for the treatment of Glioblastoma Multiforme (GBM), a rare but aggressive form of brain cancer. ITI-1001 is an investigational plasmid DNA vaccine therapy designed to target the pp65, IE-1 and… Read More